Risk Management



Several New and Revised Consent Forms Published by OMIC

Several new and revised informed consent documents and risk management recommendations documents were recently uploaded.

CATARACT SURGERY

  • New: Same Day Sequential Bilateral Surgery Addendum
  • New: Femtosecond Laser Cataract Surgery Addendum

RETINA

  • New: Intravitreal Anti-VEGF Injections for Adults: Risk Management Recommendations
  • Revised: AvastinTM (bevacizumab) Consent
  • Revised: EyleaTM (aflibercept) Consent
  • Revised: LucentisTM (ranibizumab) Consent
  • Revised: OzurdexTM (dexamethasone) Consent

RETINOPATHY OF PREMATURITY

  • New: Intravitreal Anti-VEGF Injections for ROP: Risk Management Recommendations
  • Revised: Intravitreal Anti-VEGF Injections for ROP Consent

See all new consent forms here.

See all new risk management recommendation guides here.

OMIC policyholders who adminster intravitreal anti-VEGF (IVAV) injections for ROP are strongly encouraged to review these forms and contact OMIC Risk Manager Anne M. Menke, RN, PhD, if you use IVAV for indications not listed on the consent form, or if you have any questions about ROP. She may be reached at 1.800.562-6642, extension 651 or amenke@omic.com.

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment



pie

Six reasons OMIC is the best choice for ophthalmologists in America.

#1. Consistent return of premium.

Publicly-traded insurance companies exist to make profits for shareholders while physician-owned carriers often return profits to their policyholders. Don’t underestimate this benefit; it can add up to tens of thousands of dollars over the course of your career. OMIC has one of the most generous dividend programs for ophthalmologists and has returned more than $20 Million to our members through dividends.

61864684